Orchid Pharma gets inspection report from US regulator
The companys stock closed 4.93% up on the BSE today
Orchid Pharma today said it has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Chennai facility.
The company has received the EIR from the US drug regulator on successful inspection closure.
According to the BSE filing, the regulator conducted the post-marketing adverse drug experience reporting inspection (PADE) at Nungambakkam, Chennai facility.
The company's stock closed 4.93% up on the BSE today.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.